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Early glycosilation products induce glomerular hyperfiltration
in normal rats
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Early glycosilation products induce glomerular hyperfiltration in nor-
mal rats. The effects of early glycosilation products (Amadori Products,
AP) were investigated in male Munich-Wistar rats to establish whether
AP play a role in the pathogenesis of glomerular hyperfiltration of early
diabetic nephropathy. To mimic such a condition, normal rats were
transfused with blood containing in vitro glycated serum (Group
GLYC) to achieve plasma levels of Amadori products similar to those
measured in rats with streptozotocin-induced diabetes. Rats transfused
with normal blood were used as control (Group CON). Glomerular
hemodynamics was evaluated in basal condition (B) and during acute
hyperglycemia (HG). Blood transfusion did not alter basal hemodynam-
ics. In Group CON, HG determined a rise of single nephron GFR(4l.4
3.2 vs. 32.1 1.8 nI/mm, P < 0.005), secondary to the increase of
afferent effective filtration pressure (EFPa, + 19% vs. B, P < 0.01). Rats
of Group GLYC, in B, had values of SNGFR higher than those of
Group CON B (46.8 3 nI/mm, P < 0.05, ANOVA). This increase was
mediated by a significant reduction of glomerular afferent arteriole (Ra,
—38% vs. Group CON B, P < 0.05), a rise in hydrostatic gradient
pressure in glomerular capillaries (P, + 17%, P < 0.05) and of EFPa(+31%, P < 0.05). During HG, a further increase of SNGFR (58.3
2.6,P < 0.005 vs. all groups) was detected in rats of Group GLYC, due
to a significant rise in glomerular plasma flow (P < 0.05 vs. CON B and
CON HG), in P (P < 0.05 vs. all the groups) and EFPa (P < 0.05 vs. all
the other groups). In conclusion, this study demonstrates that glomer-
ular hyperfiltration can be reproduced in normal rats by increasing the
plasma concentration of Amadori Products to the values observed in
diabetic rats. The pattern of modifications in glomerular hemodynamics
resembles that commonly described in diabetic hyperfiltering rats.
Glomerular hyperfiltration in early stages of diabetic disease
has been widely reported both in humans and animals [1—3] and
is considered a crucial step in the development of diabetic
nephropathy [4].
Renal micropuncture studies have demonstrated that glomer-
ular hyperfiltration in diabetic rats is secondary to afferent
glomerular vasodilation and the consequent increase in glomer-
ular plasma flow, glomerular capillary pressure and effective
filtration pressure, and no significant change in the glomerular
ultrafiltration coefficient [2, 3, 5]. A number of studies have
been previously performed to identify the specific factor(s)
responsible for such hyperfiltration. In recent years special
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attention has been focused on the hormonal mediators of renal
vasodilation such as prostaglandins [6, 7], glucagon [8], growth
hormone [9], and ANF [10]; but results have been inconclusive,
sometimes even contradictory.
In our opinion, inadequate attention has been devoted to the
metabolic aspect of the disease, since it has been reported that
a strict metabolic control of diabetes (by insulin) can prevent
hyperfiltration in the experimental animal [11], whereas the
poor control of glycemia accelerates the occurrence of glomer-
ular hyperfiltration [12].
Indeed, hyperglycemia (HG) has been claimed to play a role
in the pathogenesis of the phenomenon; but the modest rise of
GFR, acutely induced by i.v. infusion of hypertonic glucose
either in humans [1, 13] or in animals [14] is in clear contrast
with the dramatic increase of GFR (25 to 40%) occurring in
early stages of diabetic disease.
It should be stressed, however, that the persistent hypergly-
cemia of diabetes enhances the process of nonenzymatic gly-
cation of plasma proteins, thereby leading to the production of
the so-called "advanced glycosilation end-products" (AGEs)
[15].
The formation of AGEs is a three-step process [16]. The first
step is the reaction between glucose and a free amino-group of
plasma protein that leads to the formation of the so-called
"Schiff base", a highly unstable compound. The second step
(over a few weeks of hyperglycemia) is the formation of "early
glycosilation products" (EGPs), also defined as "Amadori
Products", quite stable compounds, that can be slowly disso-
ciated by correcting hyperglycemia. The third and final step
(over months or years of hyperglycemia) is the polimerization
of EGPs and the consequent formation of AGEs, irreversible
compounds responsible for some of the organ damages of
diabetes. AGEs, in fact, are commonly believed to play a key
role in determining the diabetic microangiopathy since they can
bind to long-lived proteins modifying their structure [15]; more-
over, they can also react with endothelial cells, modulating their
functional properties [17, 18].
On the basis of these properties of AG Es, it is reasonable to
believe that the process of plasma glycation strongly influences
the clinical course of untreated diabetes. It is also possible that
not only AGEs, but even Amadori Products are involved in the
diabetic dysfunction of endothelial cells, since Amadori Prod-
ucts have also been demonstrated to have a specific binding
property to endothelial cells [19].
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Glomerular hyperfiltration is present in early stages of renal
disease, when AGEs have not been formed as yet. In these
stages, however, high plasma levels of Amadori Products are
already observed, suggesting the possibility that these sub-
stances are involved in causing glomerular hyperfiltration.
The aim of our study, therefore, was to test the effects of
Amadori Products on glomerular dynamics, to evaluate
whether these substances play a role in the pathogenesis of
glomerular hyperfiltration in the early stage of diabetic nephrop-
athy. A particular experimental model was created in which
normal rats (that is, rats free of diabetic disease) were trans-
fused with in vitro glycated plasma, rich in Amadori Products,
in order to obtain plasma levels of Amadori Products similar to
those previously observed in diabetic rats. This experimental
model, while emulating a fundamental metabolic aspect of
diabetes (that is, the glycation of plasma proteins), is devoid of
any influence of hormonal changes (that are commonly induced
by diabetes and may modify renal hemodynamics) and glomer-
ular pathology (such as glomerular hypertrophy, that is com-
monly present in diabetic hyperfiltrating rats).
Glomerular dynamics was evaluated, by renal micropunc-
ture, in normal and "glycated" rats in basal condition and after
acute hyperglycemia, to compare the effects of hyperglycemia
with those of Amadori Products alone, and to evaluate their
combined effects in glycated rats, that is, in a condition that
maximally simulates that of the early stage of diabetes.
Methods
Male Munich Wistar (MW) rats were used in the study. Their
body weight averaged 221 g (range 192 to 243). The rats were
bred in our facility and had water and standard pellet food
(protein content: 20% as casein) ad libitum.
Evaluation of early glycosilation products (Amadori
Products) in diabetic and normal rats
Eight male Munich Wistar rats were made diabetic by a single
i.p. injection of streptozotocin (65 mg/kg), dissolved in buffer-
citrate. Blood glucose levels were monitored in tail blood
samples after two days and, then, every five to seven days in
order to maintain the rats moderately hyperglycemic (glucose
levels ranging between 350 and 400 mg/dl) by s.c. administra-
tion of small doses of ultralente insulin (0.6 to 0.8 lU/day). For
measuring serum levels of Amadori Products, blood samples
(0.4 ml) were obtained, under a light ether anaesthesia, by
cardiac puncture every two weeks up to six to eight weeks from
the occurrence of diabetes, when diabetic rats with moderate
hyperglycemia are known to be hyperfiltrating [3, 5].
Twelve normal rats were used as control for determination of
basal plasma values of Amadori Products.
All blood samples were cold-centrifuged (4°C); serum sam-
ples were immediately stored at —30°C until the time of assay.
Determination of early glycosilation products (Amadori
Products)
Amadori products were measured in blood samples collected
from normal and diabetic rats. Measurement was performed in
duplicate, as fructosamine concentrations in plasma by the nitro
blue tetrazolium (NBT) method [201. Briefly, the different
points of the standard curve were obtained by appropriate
dilutions of a solution containing 6 mg of 1 -deoxy- 1 -morpholi-
nofructose (DMF) and 40 mg of rat albumin dissolved in 1 ml of
a carbonate-buffer solution (0.1 M, pH 8). For the colorimetric
reaction, 950 p1 of a carbonate buffer solution (0.1 M, pH 8)
containing 0.6 mg of nitro blue tetrazolium (NBT) were added
to each sample of the standard curve (50 p1) and each plasma
sample to be tested (50 p1). After 15 and 17 minutes the samples
were read by a spectropothometer, at a wave length of 550 m,
and the difference between the two readings was used to
determine the linear regression analysis and the concentration
of early glycosilation products in each sample, expressed as
mmollliter of fructosamine.
Serum glycation in vitro
The formation of Amadori Products is influenced by concen-
tration of glucose, temperature and pH [161. Therefore, to get a
high concentration of them, normal serum (from blood samples
obtained by cardiac puncture) of male MW donor rats was
incubated at 37°C, with a full sterile procedure, with very high
concentration of glucose (450 mM) for eight days. Preliminary
studies had demonstrated that such a concentration of glucose
gives the greatest production of Amadori Products in this
restricted period of incubation; the longer incubation time, in
fact, may induce the formation of AGEs [17]. The serum was
then dialyzed for 24 hours against a bicarbonate-saline solution
to remove unbound glucose through a cellulose membrane
(Roth 1780.1, cut-off size: 12,000 daltons). The concentration of
Amadori Products was then measured by the NBT reaction.
Blood transfusion in rats
Plasma levels of Amadori Products (AP) in diabetic rats,
seven weeks after the occurrence of diabetes, were, on the
average, twice the plasma concentrations in normal rats ( see
Results). Thus, to mimic the condition of diabetes, we had to
double the amount of AP in serum of normal rats by transfusing
in vitro glycated serum. The absolute amount of AP present in
each rat (which represents, of course, the same amount to be
transfused) was therefore calculated on the basis of plasma
volume (PV), measured in six unmanipulated MW rats,
matched for age and body weight, by the Evans blue method
[211, and the basal values of AP, according to the formula:
AP X (PV X body weight)
This value, divided by the AP concentration of in vitro glycated
serum, indicated the amount of serum to be transfused. In such
calculation the amount of AP withdrawn with the arterial blood
at time of transfusion was taken into account in order to have it
replaced by additional amounts of glycated serum (see below).
Glycated serum to be transfused was added to red blood cells
(freshly collected from "donor" rats and twice rinsed with
sterile saline) in order to obtain Hct values averaging 46 to 50%.
For transfusion, the rats were lightly anaesthetized with ether
(in the morning), and the right femoral vein and artery were
catheterized with polyethylene tubing (PESO). To avoid volume
expansion, an amount of normal blood, equal to that transfused,
was collected through the arterial line by a syringe, while the
"glycated" blood was infused through the femoral vein. Actu-
ally, such infusion started when the first 2 ml of arterial blood
were withdrawn, in order to prevent the "hemodilution" of in
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Table 1. Effects of acute hyperglycemia and of early glycosilation products (EGPs) on mean arterial pressure (MAP), hematocrit (Hct), urine
output (V), plasma protein concentration (Ca), and one-kidney GFR (GFR)
MAP Hct V Ca GFR
mm Hg % j.zJ/min gid! mi/mm
CON B 109 3.4 46.4 0.9 6.8 1.6 5.1 0.2 0.75 0.06
value NS 0.005 0.001 0.05 NS
CON HG 115 2.3 44.0 1.0 21.8 4.32 4.7 0.2 0.91 0.08
GLYC B 105 3.7 46.7 1.5 3.2 0.2 5.2 0.1 1.01 o.o6
value NS 0.001 0.001 0.01 0.02
GLYC HG 110 3.6 41.6 1.6 12.7 2.4a 4.3 0.2 1.26 0.06"
Data are expressed as means SEM. Abbreviationsare: CON, control group; GLYC, rats transfused with EGPs; B, basal period and HG, acute
hyperglycemia period in both groups.
Data are by ANOVA, Bonferroni's test; minimum P value < 0.05.
a Significantly different vs. CON B
"Significantly different vs. CON B and CON HG
vitro glycated serum. Both vessels were tightly ligated, and the
surgical wound was sutured and disinfected. These rats were
defined glycated" rats constituting Group GLYC. The control
group (Group CON) underwent a similar surgical procedure,
but received normal, non-glycated blood from donors rats (1.5
ml/100 g body wt). Four additional rats were transfused with
serum that was incubated in vitro for eight days, but with low
amounts of glucose (5 mM), in order to establish whether the
process of incubation could be somehow responsible for any
modification of renal dynamics; these rats underwent a surgical
procedure comparable to that of micropuncture experiments
(see below) but were investigated by renal clearances. Rats in
which the complete procedure of blood transfusion exceeded 20
minutes from the beginning of anaesthesia were discarded, to
avoid undesired effects of prolonged ether anaesthesia. After
surgery, the rats were allowed food and water ad libitum. To
test whether this surgical procedure and/or blood transfusion
may have influenced baseline glomerular dynamics, four unma-
nipulated, normal rats were studied by renal micropuncture.
Micropuncture studies
Forty-eight hours after transfusion, rats were prepared for
renal micropuncture, according to our technique [22]. The
study was carried out on 26 rats, overnight fasting but with free
access to tap water. Surgical procedure for micropuncture is
described elsewhere [23, 24]. Experiments were carried out in
"euvolemia" (with infusion of 1 ml of rat serumf 100 g body wt
during the 60-mm stabilization period, followed by 0.15 ml/hr).
Rats of Group GLYC received the same "glycated" serum used
for blood transfusion, although properly diluted with normal
serum (1:2.5). A bicarbonate saline solution, containing 5%
chemical inulin, was also administered at an infusion rate of 1.2
mI/hr. After the 60-minute stabilization period, experimental
determinations were started in each rat with the measurement
of hydrostatic pressures, and the collection of fluid and plasma
samples in a randomized fashion. Hydrostatic cortical pres-
sures were directly measured in glomerular capillaries (Pg), in
tubules (Pt) and in star vessels by a servo-nulling device (1PM,
San Diego, California, USA) connected to a dual channel
recorder (7702 B, Hewlett-Packard, Elkhart, Indiana, USA),
using pipettes with outer tip of 2 to 3 jim filled with 1 M stained
NaCl solution. Furthermore, at least four timed complete
tubular fluid collections were performed in the same rats for
inulin determination and calculation of SNGFR, using micropi-
pettes of 8 to 10 jim O.D. Two to four blood samples were
collected from star vessels, with 15 jim sharpened heparinized
micropipettes, to determine efferent protein concentration. In
coincidence with tubular fluid and peritubular blood collections,
femoral arterial blood samples (70 jil each) were obtained for
determination of hematocrit, plasma inulin and protein concen-
tration. These measurements lasted less than one hour and
constituted the basal determinations (B). Then, an i.v. infusion
of hypertonic glucose (33% wt/vol) was started at a constant
infusion rate of 30 jiu/min and maintained for at least 20 minutes
until blood glucose levels (measured by an automatic glucotest)
reached values ranging between 350 and 400 mg/dl. The infusion
rate was then reduced to 15 to 18 jil/min to allow a stabilization
of glucose concentration. The micropuncture study was re-
peated during acute hyperglycemia (HG). At the end of this
second period, a blood sample was collected in six glycated rats
for determination of Amadori Products, as previously de-
scribed. Rats in which any of the two periods under study
exceeded 60 minutes were discarded. Eight rats in each group
underwent the complete two-period study; five further rats in
each group served as time control and were examined, by
micropuncture, at the time corresponding to the period of acute
hyperglycemia in the other rats, to evaluate whether a three-
hour infusion period had enhanced the acute effects of hyper-
glycemia on glomerular dynamics.
Analytical determinations
Inulin concentration in plasma samples was determined by
diphenylamine method [25]. Urine volume was determined by
weight difference. For microsample determinations, the volume
of tubular fluid collected from individual nephrons was esti-
mated from the length of the fluid column in a constant bore
capillary quartz tube of known internal diameter. The concen-
tration of inulin in tubular fluid was measured in duplicate by
the micro-fluorescence method of Vurek and Pegram [26].
Systemic and star vessel plasma protein levels were measured
in duplicate by a microadaptation of Lowry's method [27]. In all
analytical determinations, the standard curves were determined
by linear regression analysis; the correlation coefficient of these
curves was always greater than r = 0.996.
Statistics
The Student's t-test for paired data was used to evaluate the
differences between the basal and hyperglycemic period in each
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Table 2. Effects of acute hyperglycemia (HG) and of early glycosilation products on glomerular dynamics
SNGFR AAPF EAPF AABF EABF Pg Pt P Psv
nI/mm mm Hg
CON B 32.1 1.8 130.7 10.1 99.1 9.8 246.9 22.3 214.8 21.2 46.2 0.4 13.3 0.2 32.8 0.4 15.4 0.3
t-value 0.005 NS NS NS NS 0.005 0.005 NS NS
CON HG 41.4 3.2 147.3 14.4 105.8 11.2 265.0 28.1 223.5 28.0 49.2 0.9 15.4 0.6c 33.8 1.3 14.6 0.4
GLYC B 46.8 3.0° 169.4 6.7 122.6 6.3 318.8 15.3 271.9 13.2 51.7 0•6b 13.3 0.1 38.4 0.7" 14.2 0.3
t-value 0.005 NS NS NS NS 0.001 0.001 0.05 NS
GLYC HG 58.3 2.6" 199.4 12.8" 141.0 11.1 343.8 23.6° 297.9 24.1 55.7 0.2" 15.1 0.3° 40.8 04b 13.9 0.4
Data are expressed as means SEM. Abbreviations are: SNGFR, single nephron GFR; AAPF and EAPF, afferent and efferent arteriole
glomerular plasma flow, respectively; AABF and EABF, afferent and efferent arteriole glomerular blood flow, respectively; Pg, hydrostatic
pressure in glomerular capillaries; Pt, intratubular pressure; .P, hydrostatic pressure gradient across glomerular capillaries, Psv, star vessels
pressure; Ce, efferent arteriole protein concentration; SNFF, single-nephron filtration fraction; EFPa and EFPe, afferent and efferent effective
filtration pressure, respectively; Rt, total glomerular vascular resistance; RA and RE, afferent and efferent glomerular arteriolar resistance; Kf,
ultrafiltration coefficient. Groups abbreviations are the same as in Table 1. Data are by ANOVA, Bonferroni's test; minimum P value < 0.05.
a Significantly different vs. CON Bb Significantly different vs. CON B and CON HG
Significantly different vs. GLYC B
d Significantly different vs. all the other groups
single group. The one-way analysis of variance (ANOVA) was
used to evaluate the differences between the four experimental
periods. The Bonferroni's test was used to identify differing
mean values. A P value <0.05 was considered statistically
significant. Data are expressed as means SEM.
Abbreviations used in this study are listed in the Appendix.
Results
Determination of plasma levels of Amadori Products in
diabetic rats and plasma volume in normal rats
Plasma glucose in diabetic rats averaged 356 23 mg/dl.
Plasma concentration of Amadori Products in diabetic rats
showed a tendency to rise in the third week after the adminis-
tration of STZ, and reached the highest value in the fifth to the
seventh week, when plasma levels of Amadori Products were
more than double compared to control rats (3.91 0.6 vs. 1.71
0.2 mmol/liter, P < 0.001).
Plasma volume, calculated by Evans' Blue method in normal
rats, was 4.01 0.3 ml/lOO g of body wt. Since the mean
concentration of Amadori Products in in vitro glycated serum
was 9.3 2.5 mmol of fructosamine/liter, the amount of blood
to be transfused in glycated rats (taking into account also the
amount of Amadori Products withdrawn from femoral artery
during blood transfusion) ranged between 2.5 and 4 ml. Protein
concentration of glycated sera averaged 4.91 0.1 g/dl, a value
similar to that observed in rats of our study. In vitro incubated
serum with small amounts of glucose had lower values of
Amadori Products (1.06 0.2 mmol of fructosamine/liter),
whereas protein concentration did not change.
Renal and glomerular dynamics
In normal rats, blood transfusion with normal, nonglycated
serum did not alter any of the determinants of glomerular
ultrafiltration, when compared with four normal, non-trans-
fused rats; therefore four transfused rats and the four non-
transfused rats were joined together in Group CON (Table I).
Body weight was similar between the two groups of rats (218
24 gin CON and 223 21 g in GLYC, respectively). Baseline
data (B) of rats of Group CON and rats of Group GLYC did not
show differences in mean arterial blood pressure (MAP), nor in
urinary volume (V), plasma protein concentration (Ca), or
hematocrit value (Hct), thereby indicating that transfusion of
glycated serum did not result in plasma volume expansion.
One-kidney GFR, on the other hand, was significantly higher in
Group GLYC (+35% vs. CON B, P < 0.01). Rats transfused
with serum incubated with low amounts of glucose did not show
any difference with either GLYC or CON rats in MAP, V, Ca or
Hct. Their GFR averaged 0.77 0.07 mI/mm, a value which
overlapped that of CON rats.
Acute hyperglycemia (HG) was induced in CON and GLYC
groups by the administration of comparable amounts of hyper-
tonic glucose solution, and resulted in similar plasma levels of
glucose (337 41 mg% in Group CON and 323 28 in Group
GLYC) and no significant difference in MAP. Urinary volume
was strikingly increased by HG when compared with basal
value in both groups. GFR was augmented by HG, although not
significantly, in Group CON (+ 22%). In rats of Group GLYC
(which had baseline values of GFR significantly higher than
those of CON B rats) glomerular filtration rate was further
increased during HG (+25%, P < 0.02 vs. GLYC B), resulting
in significantly higher values than those observed in either
condition of CON rats.
The concentration of Amadori Products in blood collected
from six rats of Group GLYC averaged 4.3 1.23 mmol!liter of
fructosamine, a value similar to that observed after seven
weeks of experimental diabetes in rats.
Acute effects of hyperglycemia (HG) in normal rats (Group
CON)
Renal micropuncture data are depicted in Table 2.
SNGFR was significantly increased during acute HG (+29%,
P < 0.005 vs. B); such an increase was not mediated by
modifications of glomerular plasma (AAPF) or blood flow
(AABF) which remained unchanged; thus SNFF was slightly
(but not significantly) increased. HG, in fact, did not alter total
glomerular resistances (Rt) nor the intraglomerular pattern of
afferent (RA) and efferent (RE) resistances (the ratio RE/RA was
similar between B and HG periods). The glomerular hydrostatic
pressure gradient (P) was unchanged during HG since the
significant increase of Pg (+6.5%, P < 0.005 vs. B) was
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Table 2. Continued
Ce
g/di SNFF
EFPa EFPe Rt RA RE
mm Hg dyne/sec/cm5 RE/RA
K
ni/sec/mm Hg
6.9 0.2
NS
6.6 0.2
7.2 0.1
0.05
6.1 0.2
0.25 0.01
NS
0.29 0.02
0.27 0.01
NS
0.29 0.01
16.5 1.1 7.8 1.6 3.16 0.28 2.01 0.19 1.15 0.11 0.58 0.04
0.01 NS NS NS NS NS
19.7 1.3 10.1 1.5 3.37 0.38 2.08 0.27 1.28 0.13 0.64 0.04
21.7 0.8a 11.3 1.1 2.30 0.14 1.24 011b 1.05 0.06 0.89 0.08a
0.001 0.01 NS NS NS NS
27.2 1.1" 19.5 1.7" 2.44 0.13 1.20 006b 1.21 0.12 1.02 0.09"
0.049 0.010
NS
0.051 0.010
0.046 0.007
NS
0.041 0.006
Table 3. Main determinants of glomerular ultrafiltration in time control rats
SNGFR Ht Pg EFPa RA
CON (N = 5)
GLYC (N = 5)
34.9 1.0 45.4 1.3 46.1 0.4 17.1 0.7
45.6 2.7 44.6 1.6 51.2 0.2 20.6 0.7
2.097 .15
1.201 .25
Data are expressed as means SEM. For abbreviations and units, see other tables.
counterbalanced by a significant rise of Pt (+ 16%, P < 0.005 vs.
B); no modification occurred in star vessel hydrostatic pres-
sure. Protein concentration in systemic blood (Ca) decreased
significantly during HG (Table 1), as a result of glucose-induced
plasma volume expansion (—8%, P < 0.05 vs. B). This caused
afferent effective filtration pressure (Table 2) to rise by 19% (P
<0.01 vs. B). The ultrafiltration coefficient (Kf) was unmodified
by HG.
Effects of Amadori Products on glomerular dynamics (Group
GL YC)
In basal condition rats of Group GLYC had SNGFR values
higher than those observed in rats of group CON in basal
condition (+31%, P < 0.05; Table 2). These rats had higher
baseline value of AAPF when compared to rats of Group CON
in basal condition (+29%), although this value did not achieve
statistical significance. SNFF was similar to that observed in
rats of Group CON B. Total glomerular resistances (Rt) were
not significantly decreased (—27% vs. rats of Group CON B,
NS), but the intraglomerular pattern of such resistances was
deeply modified by a sharp decrease of RA (—38%, P < 0.05)
with R unchanged; this determined a significant rise of the
ratio RE/RA (+53%, P < 0.01). As a consequence of the afferent
vasodilation, Pg was markedly increased (+ 12%, P < 0.05);
since Pt remained unchanged, a significant increase of both LP
(+ 17%, p < 0.05 vs. CON B) and EFPa (+31%, P < 0.05) was
observed. EFPe values were similar to those obtained in rats of
Group CON B.
With respect to the HG period of rats of Group CON,
glycated rats in basal condition showed higher values of
SNGFR (+ 13%, NS), associated with a small increase of AAPF
(+ 15%, NS).
Thus, in basal conditions these rats (GLYC B) were hyper-
filtering. Concerning the determinants of glomerular ultrafiltra-
tion, the rise in GFR was secondary to factors different from
those mediating the increase of SNGFR in CON HG, and more
closely approaching those described to occur in diabetic rats,
that is, fall of RA, increase of AAPF, Pg, and EFP.
During acute hyperglycemia, rats of Group GLYC showed a
further increase of SNGFR (+24% vs. GLYC B, P < 0.005).
With respect to the basal period, such an increase was mediated
by a significant increment in Pg (+7.7%, P <0.001) and, despite
the higher Pt values (+ 13%, P < 0.001), i.P (+6%, P < 0.05)
and EFPa (+25%, P < 0.001). AAPF was only slightly higher
than in basal condition, but its values resulted significantly
higher than those calculated in rats of Group CON, in both
experimental conditions. Kf was not modified.
Timed control rats (Table 3), despite a tendency of Hct to
decrease with time, showed a trend to a numerical increase of
SNGFR only in Group CON, but no change in the pattern of
glomerular resistances and Pg: thus, that an expansion of
volume had influenced the results obtained during HG could be
reasonably excluded.
Discussion
This study provides evidence that glomerular hyperfiltration
can be induced in normal rats by transfusing blood containing
early products of glycosilation (Amadori Products), suggesting
that the formation in vivo of adequate amounts of Amadori
Products are a necessary step for the increase of GFR occurring
early in the course of diabetic nephropathy. The absence of
modifications in renal dynamics observed in rats transfused
with serum incubated with low amounts of glucose assures that
the process of incubation in vitro has no effect (either direct or
indirect) on renal dynamics, and further suggests the crucial
role of such products of early glycosilation in mediating hyper-
filtration.
The experimental model used in our study represents a
unique opportunity to investigate the effects of Amadori Prod-
ucts on glomerular dynamics in the absence of the characteristic
"milieu" of diabetes, that is, of both humoral or structural
alterations of such a disease.
As already reported by others [14], we have observed that the
effects of acute hyperglycemia on renal and glomerular dynam-
ics were mild, certainly not sufficient to justify the huge
increase of GFR and SNGFR typical of early diabetic nephrop-
athy. In our study the only parameter of glomerular ultrafiltra-
tion that was modified during acute hyperglycemia was the
afferent EFP, that was increased as a consequence of a de-
crease in plasma proteins, likely secondary to the expansion of
plasma volume; all other determinants of glomerular ultrafiltra-
tion were not modified since the significant rise of Pg was
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counterbalanced by higher values of Pt. Similar increase of
SNGFR(by +17% vs. control) was reported by Blantz et al [141
in an experimental model of acute hyperglycemia in which
plasma volume expansion was less pronounced than in our
model, since hypertonic solution of glucose was administered
with no addition of other fluids.
In contrast with hyperglycemic rats, glycated rats exhibited,
even in basal condition (in absence of volume expansion),
glomerular hyperfiltration and hyperperfusion, that is, an in-
crease in both SNGFR and AAPF well far from the values
observed in basal condition of control rats (+45% and +30%,
respectively). Such an increase was mediated by the significant
reduction of RA (with the concomitant rise of the ratio RE/RA)
that was responsible for the increment in Pg and, in turn, in both
P and afferent EFP (in absence of any modification of MAP
and/or Kf).
Acute hyperglycemia in glycated rats, then, caused a further
impressive increase in both SNGFR (+24% vs. basal) and
AAPF (+ 18%) vs. basal) secondary to the rise in Pg, P and
afferent EFP, in the absence of significant changes of glomeru-
tar resistances, MAP and Kf. Thus, acute hyperglycemia had a
consistent additive effect on glomerular hyperfiltration induced
by Amadori Products. The overall increase of SNGFR and
AAPF between CON Bas and GLYC HG averaged +81% and
+ 52%, respectively.
An analysis of the literature shows that hyperfiltration in
moderately hyperglycemic diabetic rats is characterized by a
pattern of hemodynamic modifications similar to those ob-
served in our glycated rats, that is reduction in RA, increase in
AAPF, Pg, zP, and EFP. The increase in SNGFR observed in
basal condition of our glycated rats was quantitatively similar to
that reported in literature [2—5, 29].
In our opinion, many of the discrepancies of data in studies
performed in diabetic rats can be largely accounted for by the
different metabolic status of the animals, which influences the
plasma concentration of Amadori Products. It is widely known,
in fact, that in vivo formation and dissociation of Amadori
Products are linked to the glycemic control [161. Thus, it should
not be surprising that diabetic MW rats receiving high amounts
of insulin (4 or more lU/day) [11] exhibit lower degrees of
glomerular hyperfiltration than rats receiving small doses of
insulin (0.8 to 2 lU/day) [5, 30] or not at all [12]. On the basis of
our data, this would be the obvious consequence of a better
metabolic control of diabetes and, consequently, a reduced
generation of Amadori Products, although plasma levels of
glucose were comparable at the time of micropuncture.
Furthermore, the duration of diabetes seems to play a role in
the expression of hyperfiltration; thus, rats studied after four
weeks of diabetes are reported to have higher values of SNGFR
(vs. their respective controls) [5] than rats examined in a much
longer time course [4 to 15 weeks) [3, 29]. A possible explana-
tion is that with time the production of advanced glycosilation
end-products (AGEs) had already started [17], and it has been
recently shown that AGEs impair the release of vaso-relaxing
endothelial factors [18], thereby blunting the vasodilating re-
sponse to Amadori Products. On the other hand, rats not
treated with insulin become hyperfiltrating only a few days after
the occurrence of diabetes, independently on the strain (MW or
SD) [12, 31], because the production of Amadori Products is
surely enhanced in absence of metabolic control of glycemia.
Glomerular hyperfiltration in diabetics can be avoided or
reversed by a correct metabolic control [11]. Also in humans
[32] a strict metabolic control in hyperfiltrating diabetic subjects
decreases GFR over one week and can also reduce protein
excretion. This beneficial effect of an adequate metabolic con-
trol of diabetes in reducing glomerular hyperfiltration is, in our
opinion, accounted for by the interference with the formation of
Amadori Products.
Although this study does not clarify the mechanism(s) in-
volved in determining glomerular hyperfiltration, it offers a new
basis for studies on cells in culture. It seems reasonable, in fact,
that an interaction similar to those reported for AGEs [17, 18]
exists between endothelial cells and Amadori Products. Indeed,
it has been recently demonstrated that AGEs have specific
receptors on endothelial cells [171. The binding of AGEs to the
cells is associated with modification of both structural and
functional properties of these cells, that is, increased perme-
ability of a monolayer of endothelial cells to inulin and altered
expression of thrombomodulin on cell surface. The binding of
AGEs to their receptors is competitively inhibited by AGE-
BSA or AGE-hemoglobin.
Amadori Products also have receptors on endothelial cells
[19] which are different from AGEs receptors, since their
binding with Amadori products is inhibited by albumin, glucose
and mostly by albumin+glucose.
Concerning the mediator(s) of glomerular hyperfiltration, it is
interesting to note that Bucala, Tracey and Cerami have re-
cently demonstrated that AGEs can inhibit renal vasorelaxation
through a decreased diffusion of EDRFs from endothelial to
smooth muscle vascular cells [18]. It can be hypothesized that
Amadori Products stimulate the production and/or somehow
enhance the diffusion of EDRFs which, in turn, would mediate
glomerular vasodilation and hyperfiltration. With time, the
progressive polymerization of Amadori Products to AGEs
would end the hyperfiltration and begin the organ damage, with
occurrence of proteinuria. It is well known, in fact, that
proteinuria appears when hyperfiltration ends [1].
In conclusion, this study shows, for the first time, that
glomerular hyperfiltration can be reproduced in normal rats
simply by transfusing blood containing Amadori Products, in
absence of the hormonal and structural modifications of diabe-
tes. It also provides a new basis for exciting research with the
aim of finding the mediators of glomerular hyperfiltration in the
first stages of diabetic renal disease.
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Appendix. Abbreviations
SNGFR, single nephron GFR
SNFF, single nephron filtration fraction
AAPF and EAPF, afferent and efferent arteriole glomerular plasma
flow, respectively
Pg and Pt, cortical hydrostatic pressures in glomerular capillaries and
tubules, respectively
Sabbatini et a!: Glomerular hyperfihtration by glycosilation products 881
P, hydrostatic pressure gradient across glomerular capillaries
EFPa and EFPe, effective filtration pressure at the afferent and efferent
sites of glomerulus, respectively
RA and RE, single afferent and efferent arteriole resistance, respectively
Kf, ultrafiltration coefficient
For details concerning the calculation of the above mentioned param-
eters, see [28].
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